Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Concarlo Holdings, LLC

  • Arikha Moses, Concarlo Holdings, LLC

CONCARLO Holdings, LLC (Concarlo) is a precision medicine oncology company developing targeted solutions to diagnose and treat metastatic solid tumor cancers.

Experienced team with four decades of biotechnology and commercialization experience. Robust IP portfolio. Seeking to raise $7 MM in 2 trenches to fund IND-enabling studies, reach FIH Phase I & complete a corporate partnership.

Approximately 37,000 U.S. women will be diagnosed with metastatic ER/PR+, Her2- breast cancer this year, and despite recent advances, the median survival for these patients remains at ~2–3 y. Concarlo is developing a new class of drugs as well as a complementary diagnostic that target p27, a key on-off switch in many metastatic tumor types. Concarlo's therapeutics exhibit more potency against sensitive and resistant tumor types in vivo than CDK4 inhibitors, which are currently first-line therapy for metastatic breast cancer patients.

  • Date:Monday, February 11
  • Time:3:15 PM - 3:30 PM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23622
  • Goal for Presentation:fundraising & partnering
  • Company Website:www.concarlo.com
  • Company HQ City:Brooklyn
  • Company HQ State:New York
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$2.1 MM
  • Size of Last Investment Round:$1.5 MM
  • Previous and Current Investors:NY Seed, Angels
  • CEO/Top Company Official:Arikha Moses, PhD
  • Year Founded:2016
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:CCL-1 & CCL-2
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):2
  • Additional Information/Comments:Concarlo's lead therapeutic CCL-2 targets the protein p27Kip1, which in turn causes inhibition of CDK4 and CDK2, and represents the first therapeutic that would inhibit both of these kinases simultaneously. Our first target indication is CDK4i-resistant, metastatic breast cancer; however, our therapies potentially will have application in additional tumor types, such as pancreatic and non-small cell lung cancer. Concarlo has shown that CCL-2 prevents acquired drug resistance resulting in a prolonged response to therapy and increased patient survival. Dual therapy causes even more significant tumor regression and increases OS in in vivo studies compared to CDK4i alone. Status: Concarlo expects to submit its IND and initiate FIH in a Phase 1 study within 24 months. Concarlo also has a diagnostic asset that differentiates between CDK4i-sensitive and resistant tumors.
Speakers
Arikha Moses
Concarlo Holdings, LLC
Back